The Regulator

$1.6 billion: that is how much New York’s insurance department says it saved residents and small businesses by cutting insurers’ 2027 Affordable Care Act rate requests nearly in half, a fight playing out the same day in Delaware too. New York’s Department of Financial Services (DFS) announced September 4, 2026 that it approved 2027 individual-market health insurance rates averaging a 6.0 percent increase, far below the 20.6 percent insurers requested, and small-group rates averaging an 8.0 percent increase against a 23.7 percent request, together covering an estimated 860,000 New Yorkers and saving roughly $324 million for individual enrollees and $1.25 billion for small businesses. The same day, Delaware’s Insurance Department finalized its own 2027 marketplace rates, approving Highmark Blue Cross Blue Shield of Delaware, an insurer, at a 17.20 percent average increase against its 20.20 percent request and AmeriHealth Caritas at 13.94 percent, with Commissioner Trinidad Navarro citing the scheduled expiration of enhanced federal premium tax credits and this year’s federal budget law as cost drivers heading into open enrollment, which begins November 1, 2026. Confidence: High. This run reviewed each state’s own press release directly. Sources: Department of Financial Services Announces 2027 Health Insurance Premium Rates, Saving New Yorkers $1.6 Billion, New York DFS, Delaware Announces 2027 Marketplace Health Insurance Rates, Delaware.gov.

16 months: that is the median time patients with a common drug-resistant form of metastatic breast cancer stayed progression-free on a new pill the Food and Drug Administration (FDA) approved this week, the first cancer drug ever chosen by a blood test rather than a tissue biopsy. The FDA on September 4, 2026 granted accelerated approval to AstraZeneca’s camizestrant (brand name Etcamah) for hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer in patients whose tumors carry an ESR1 resistance mutation, its first-ever cancer approval guided by a mutation detected through a blood-based liquid-biopsy test, while simultaneously authorizing the Guardant360 CDx companion diagnostic used to identify eligible patients. In the pivotal trial, patients on camizestrant had a median progression-free survival of 16 months versus 9.2 months on the comparator hormone therapy, though the drug carries a boxed warning for irregular heart rhythm when combined with certain other therapies. Confidence: High. This run reviewed the FDA’s own approval announcement directly. Sources: FDA Grants Accelerated Approval to New Breast Cancer Treatment, U.S. Food and Drug Administration.

$34.8 million: that is how much two Florida men billed Medicare for orthotic braces patients never needed, before a federal judge sent them to prison this week. The Department of Justice announced September 4, 2026 that Kenneth Charles Kessler III, 43, of Miami, and Michael Andrew Gomez, 43, of Miramar, were sentenced to 33 and 24 months in federal prison for running seven durable medical equipment companies that billed Medicare $34.8 million for medically unnecessary braces obtained through illegal kickbacks to telemarketers and physicians, then used shell companies to keep billing after Medicare suspended their payments. Prosecutors said Kessler personally pocketed more than $1.4 million and Gomez more than $2.3 million from the scheme. Confidence: High. This run reviewed the Department of Justice’s own press release directly. Sources: Florida Men Sentenced to Prison for $34.8M Health Care Fraud Scheme Targeting Medicare Beneficiaries, U.S. Department of Justice.

1 in a million: that is roughly how rare Alexander disease is, and this week it got its first-ever FDA-approved treatment, a drug injected into the spine four times a year. The FDA approved zilganersen (brand name Zanvastro), made by drugmaker Ionis Pharmaceuticals, on September 3, 2026 as the first drug ever cleared to treat Alexander disease, a rare and often fatal neurological disorder that damages the brain’s support cells and mostly strikes infants and young children; the antisense oligonucleotide is administered intrathecally, directly into spinal fluid, once every three months, and moved through review under the FDA’s Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations. The drug’s trial recorded cases of aseptic meningitis as a notable adverse event, and pricing has not yet been disclosed. Confidence: High. This run reviewed the FDA’s own approval announcement directly. Sources: FDA Approves First Drug to Treat Alexander Disease, U.S. Food and Drug Administration.

September 18: that is the deadline a dozen congressional Democrats just gave federal regulators to explain why hospitals are still being asked to hand over patients’ identifiable emergency room records. A bicameral group of 12 Democrats led by Senators Edward Markey and Richard Blumenthal and Representatives Jan Schakowsky and Kevin Mullin sent a letter to the Consumer Product Safety Commission (CPSC), reported September 3, 2026, demanding it immediately suspend its NEISS-R data collection program, which asks up to 100 hospitals nationwide to send contractor Konza Health identifiable emergency-department records, including names, birthdates, home addresses, and diagnoses, under a five-year federal contract worth up to $15.9 million; this newsletter first covered the program’s mandatory-versus-voluntary confusion on August 31. The lawmakers set a September 18, 2026 deadline for CPSC to answer eleven questions, including why Konza’s public claim that it deletes identifiable records within 30 days conflicts with other CPSC statements about the program. Confidence: Medium. This run relied on trade-press reporting quoting the lawmakers’ letter directly; the letter itself was not independently located as a standalone document, and CPSC has not yet responded publicly. Sources: Democrats Urge Consumer Product Agency to Halt Public Health Modernization Project, Nextgov/FCW.

7,680: that is how many supervised clinical hours a Wisconsin nurse practitioner must now log before practicing without a doctor’s sign-off, under a state law that took effect this week. Wisconsin’s Department of Safety and Professional Services began issuing new Advanced Practice Registered Nurse (APRN) licenses on September 1, 2026 under the state’s APRN Modernization Act, replacing the old Advanced Practice Nurse Prescriber certification and opening a pathway to full, independent practice, without a physician collaborative agreement, for nurse practitioners who complete 7,680 total clinical practice hours. The change moves Wisconsin from a “reduced practice” state toward full practice authority, joining a growing list of states easing scope-of-practice rules to address primary-care and behavioral-health workforce shortages. Confidence: High. This run reviewed the Wisconsin Department of Safety and Professional Services’ own page directly. Sources: APRN, Wisconsin Department of Safety and Professional Services.